BG
AUTL

Bellevue Group’s Autolus Therapeutics AUTL Stock Holding History

Bellevue Group’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-41,500
Closed -$97.5K – 151
2024
Q4 		$97.5K Hold
41,500
– – ﹤0.01% 156
2024
Q3 		$151K Buy
41,500
+9,000
+28% +$35.9K ﹤0.01% 152
2024
Q2 		$113K Hold
32,500
– – ﹤0.01% 156
2024
Q1 		$207K Sell
32,500
-17,500
-35% -$109K ﹤0.01% 154
2023
Q4 		$322K Buy
+50,000
New +$191K ﹤0.01% 147
2020
Q1 		– Sell
-62,200
Closed -$821K – 218
2019
Q4 		$821K Buy
62,200
+27,600
+80% +$361K 0.01% 152
2019
Q3 		$430K Buy
34,600
+600
+2% +$7.93K 0.01% 186
2019
Q2 		$547K Buy
+34,000
New +$760K 0.01% 144

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group's AUTL Position: Q1 2025 in Review

Bellevue Group sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 41,500 shares — an estimated $97.5K sold.

Bellevue Group first reported a position in AUTL in Q2 2019 and held it in 8 quarters. The position peaked at $821K in Q4 2019. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Bellevue Group reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bellevue Group sold 41,500 Autolus Therapeutics shares in Q1 2025, an estimated $97.5K.
  • Bellevue Group first reported a position in Autolus Therapeutics in Q2 2019 and held it in 8 quarters.
  • Bellevue Group's Autolus Therapeutics position peaked at $821K in Q4 2019.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Bellevue Group's 13F filing for Q1 2025, filed 14 May 2025.